[1]朱云松,徐安平,何恢绪,等.单剂半量赛尼哌预防移植肾急性排斥的临床观察[J].南方医科大学学报,2006,(12):1818-1820.
 ZHU Yun-song,XU An-ping,HE Huei-xu,et al.Half-dose Zenapax for acute rejection prevention after renal transplantation[J].,2006,(12):1818-1820.
点击复制

单剂半量赛尼哌预防移植肾急性排斥的临床观察()
分享到:

《南方医科大学学报》[ISSN:/CN:]

卷:
期数:
2006年12期
页码:
1818-1820
栏目:
论著·临床研究
出版日期:
2000-01-01

文章信息/Info

Title:
Half-dose Zenapax for acute rejection prevention after renal transplantation
作者:
朱云松; 徐安平; 何恢绪; 范礼佩; 聂海波; 吕军; 胡卫列; 李清荣; 邓志雄;
广州军区广州总医院泌尿外科; 中山大学第二附属医院肾内科; 南方医科大学珠江医院肾移植科; 广州军区广州总医院泌尿外科 广东广州510010; 广东广州510120; 广东广州510010; 广东广州510282;
Author(s):
ZHU Yun-song1XU An-ping2HE Huei-xu1FAN Li-pei3NIE Hai-bo1NV Juen1HU Wei-nie1LI Qing-rong1DEN Zhi-xiong1 1Department of UrologyGuangzhou General Hospital of Guangzhou CommandGuangzhou 510010China;2Department of Organ TransplantationFirst Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510080China;3Department of Renal TransplantationZhujiang HospitalSouthern Medical UniversityGuangzhou 510282China
关键词:
肾移植 赛尼哌 急性排斥
Keywords:
renal/transplantation acute rejection Zenapax
分类号:
R699.2
摘要:
目的观察单剂半量赛尼哌对肾移植急性排斥(AR)的预防作用及安全性评估。方法选择同期肾移植病人187例,根据术后肾功能恢复情况及术前是否使用赛尼哌分为A/90例、B/73例、C/11例、D/13例4组,其中A、B组移植后肾功能恢复良好,即术后1周血肌酐<176.6μmol/L,C、D组术后出现移植肾功能延迟恢复,术后1周血血肌酐>353μmol/L。A、C两组术前2h静滴赛尼哌25mg(0.5mg/kg)和口服霉酚酸酯0.75g,B、D组仅口服霉酚酸酯0.75g;术后四组病人均予甲基强的松龙500mg×3d冲击,常规强的松、环孢霉素A和霉酚酸酯三联抗排斥治疗。观察术后6个月内AR发生率、发生时间、强度及排斥逆转率,同时观察胃肠道反应、感染及血液系统损害等副作用。结果A组13例(14.4%)发生AR,B组18例(24.6%),C组6例(54.5%),D组7例(53.8%),A组AR发生率明显低于B、C、D三组(P均<0.01);B组AR发生率显著低于C、D组(P<0.01),C、D组差异不显著(P>0.05),A组排斥开始时间3-9d(6.2±3.2d)较B组2-8d(4.5±3.1d)、C组2-7d(4.3±4.2d)、D组2-9d(3.9±3.5d)明显延迟(P均<0.05)。但B、C、D三组排斥开始时间无明显差异(P>0.05)。A组AR经强化治疗均逆转,B组16例逆转,另2例失败,C组5例逆转,1例因移植肾排斥破裂出血切除,D组5例逆转,2例失败;C、D组各2例于术后13-32d再次排斥,经甲基强的松龙强化治疗逆转。感染、胃肠道反应及血液系统损害四组差异不显著(P均>0.05)。结论移植后肾功能恢复良好病人,术前25mg赛尼哌可显著降低AR发生率,且安全性好。但对于移植肾功能延迟恢复病人,术前25mg赛尼哌并不能有效预防排斥发生。
Abstract:
Objective To investigate the efficacy and safety of half-dose Zenapax for prevention of acute rejection after renal transplantation.Methods According to the immunosuppressive regimen and renal function after transplantation,patients were divided into 4 groups,namely groups A,B,C,and D of 90,73,11 and 13 patients,respectively.Blood creatinine measured 1 week after operation was <176.6 μmol/L in groups A and B,and was >353 μmol/L in groups C and D.Patients in groups A and C were given 25 mg Zenapax(0.5 mg/kg)and MMF 0.75 g before operation,and those in groups B and D had only MMF of 0.75 g.All patients were given Pred,CsA and MMF after operation,and the rejection episodes,the time of acute rejection onset,the rate of rejection reversal and complications were analyzed in the time period of 6 months after operation.Results After the operation,13 patients(14.4%)developed acute rejection in group A,18(24.6%)in group B,6(54.5%)in group C and 7(53.8%)in group D(P<0.01).The incidence of acute rejection in group B was significantly lower than that in groups C and D groups(P<0.01),and the latter two groups had similar incidence.The time of acute rejection onset ranged from 3 to 9 days postoperatively(mean 6.2±3.2 days)in group A,significantly delayed as compared with that in group B(range 2-8 days,mean 4.7±3.1days),group C(range 2-7 days,mean 4.3±4.2 days)and group D group(range 2-9 days,mean 3.9±3.5 days),but the time was similar between groups B,C,and D(P>0.05).All acute rejection cases in group A was reversed,and the rate of reversal was 88.9%(16/18)in group B,83.3% in group C,and 71.4% in group D.No significant differences were noted in such complications as infection,vascular injuries or gastrointestinal reactions between the 4 groups(P>0.05).Conclusion Zenapax at the dose of 25 mg can safely decrease the risk of acute rejection in patients with good postoperative renal function recovery,but dose not seem effective in patients with delayed graft function recovery.

相似文献/References:

[1]刘丁,蔡绍曦,刘永光,等.肾移植术后侵袭性肺部真菌感染的预后因素分析——单中心10年经验回顾性分析[J].南方医科大学学报,2011,(05):882.
[2]黄君,吴英,苏泽轩,等.移植肾术后早期肾动脉阻力指数与血肌酐值的相关性分析[J].南方医科大学学报,2011,(06):1105.
[3]司中洲,李亭,李杰群,等.白细胞介素-17 与Th17 细胞在小鼠肾移植急性排斥反应中的表达及意义[J].南方医科大学学报,2011,(08):1374.
[4]石向华,刘小友,孙煦勇,等.CD40 阻断剂对大鼠肾移植急性排斥反应的影响[J].南方医科大学学报,2011,(12):2085.
[5]于立新,熊海云,付绍杰,等.移植肾动脉狭窄危险因素对比研究[J].南方医科大学学报,2006,(08):1160.
 YU Li-xin,XIONG Hai-yun,FU Shao-jie,et al.Retrospective study of the risk factors of transplant renal artery stenosis[J].,2006,(12):1160.
[6]王平贤,范明齐,黄赤兵,等.转化生长因子β1对远期移植肾功能影响的临床观察[J].南方医科大学学报,2006,(09):1352.
 WANG Ping-xian,FAN Ming-qi,HUANG Chi-bing,et al.Influence of transforming growth factor β1 on long-term renal allograft function[J].,2006,(12):1352.
[7]聂海波,何恢绪,李逊,等.肾移植术后新尿路梗阻的临床处理(附16例报告)[J].南方医科大学学报,2005,(11):1454.
 NIE Hai-bo,HE Hui-xu,LI Xun,et al.Management of urinary obstruction following renal transplantation:report of 16 cases[J].,2005,(12):1454.
[8]于立新,王志鹏,付绍杰,等.丙型肝炎病毒感染对肾移植术后影响的临床研究[J].南方医科大学学报,2004,(06):682.
 YU Li-xin,WANG Zhi-peng,FU Shao-jie,et al.Hepatitis C virus infection and clinical outcome of kidney transplantation[J].,2004,(12):682.
[9]黄先恩,范礼佩,李留洋,等.致敏受者肾移植急性排斥反应的影响因素[J].南方医科大学学报,2004,(10):1188.
 HUANG Xian-en,FAN Li-pei,LI Liu-yang,et al.Risk factors of acute rejection in sensitized kidney transplant recipients[J].,2004,(12):1188.
[10]黄先恩,夏穗生,李留洋,等.影响致敏患者移植肾存活的危险因素分析[J].南方医科大学学报,2004,(02):121.
 HUANG Xian-en,XIA Sui-sheng,LI Liu-yang,et al.Risk factors for graft survival in sensitized recipients of kidney transplantation[J].,2004,(12):121.

更新日期/Last Update: 1900-01-01